行情

BPMC

BPMC

蓝图医药
NASDAQ

实时行情|Nasdaq Last Sale

74.00
+2.04
+2.83%
交易中 15:05 10/15 EDT
开盘
72.14
昨收
71.96
最高
74.36
最低
71.93
成交量
9.05万
成交额
--
52周最高
102.98
52周最低
44.58
市值
36.35亿
市盈率(TTM)
-9.8604
分时
5日
1月
3月
1年
5年

分析师评级

13位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BPMC 新闻

  • 邓普顿基金明星经理失手 旗舰债基三个月亏30亿美元
  • 新浪美股.47分钟前
  • 一文看懂谷歌秋季发布会:AI串联全家桶
  • 新浪科技.1小时前
  • 高盛表示已将持有的WeWork股权减记了8000万美元
  • 新浪美股.1小时前
  • 德国警告英国脱欧将推迟 协议不足以解决技术性问题
  • 新浪美股.2小时前

更多

所属板块

生物技术和医学研究
+2.03%
制药与医学研究
+1.31%

热门股票

名称
价格
涨跌幅

BPMC 简况

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
展开

Webull提供Blueprint Medicines Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。